07.05.2018 | Klinische Studien | Ausgabe 3/2018
Janus-Kinase-Inhibitor Baricitinib bei rheumatoider Arthritis
Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Therapy (RA-BEAM)
- Zeitschrift:
- rheuma plus > Ausgabe 3/2018
- Autoren:
- Prof. Dr. R. Alten, S. Nitschmann
Wichtige Hinweise
Erstveröffentlichung in Internist (2017) 58:1341–1344. https://doi.org/10.1007/s00108-017-0345-6